COVID-19/Coronavirus Archives - Society of Chemical Manufacturers & Affiliates | Society of Chemical Manufacturers & Affiliates

Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen’s COVID-19 Therapeutic Candidate Lenzilumab

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.

September 16, 2020

COVID-19 Resources for the Specialty Chemical Industry

COVID-19 Resources for the Specialty Chemical Industry SOCMA continues to monitor the impacts of COVID-19 on business continuity related to... View Article

May 22, 2020

OSHA Revises Guidances on COVID-19 Recordkeeping & Enforcement

OSHA has issued two revised guidance memos on recordkeeping and enforcement in response to the COVID-19 pandemic. On May 26, 2020, the previous memos from April on these topics will be rescinded, and the new memos will go into and remain in effect until further notice.

May 20, 2020

Demographics Show Positive Outlook for Post-COVID Economy

Internationally respected demographer, Ken Gronbach, stated the U.S. economy would not suffer as a result of COVID-19 because of it's position in the global landscape.

May 14, 2020

SOCMA Safety Solutions and Core Considerations for Reintegrating Employees Back into the Workplace

In this post, SOCMA shares the following core considerations for developing return to work plans. The following information was compiled based on information shared during a SOCMA roundtable with DanChem, Strem Chemicals, Inc and Sun Chemical Corporation. A template return to work plan is in development and will be available in the coming week.

May 8, 2020

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna, Inc. and Lonza Ltd. today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna's mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.

May 5, 2020

Categories for COVID-19/Coronavirus

Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen’s COVID-19 Therapeutic Candidate Lenzilumab

COVID-19 Resources for the Specialty Chemical Industry

OSHA Revises Guidances on COVID-19 Recordkeeping & Enforcement

Demographics Show Positive Outlook for Post-COVID Economy

SOCMA Safety Solutions and Core Considerations for Reintegrating Employees Back into the Workplace

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus

FEMA Initiative to Provide Cloth Masks to Critical Infrastructure

SOCMA Identifies High Demand Products

COVID-19 Legislative and Regulatory Issues

COVID-19 Supply Chain Updates